Pearl Ramushu

Ms. Pearl Ramushu

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2025 in Molecules
Verified
Journal Article
Open access
PDF file
PRPearl Ramushu
Pearl Ramushu
DMDikgale D. Mangoakoane
Dikgale D. Mangoakoane
RMRaymond Makola
Raymond Makola
TMTHABE MATSEBATLELA
THABE MATSEBATLELA
Lithium has been identified more than six decades ago as a preferred treatment option for manic depression. Due to its affordability, stability, minimal side effects, and immunomodulatory effects, recent studies on lithium have focused on its potential anticancer properties and possible mechanisms of action. Lung cancer ranks the highest as the main cause of death in males and has high mortality rates with low survival rates. In this study, lung adenocarcinoma (A549) cells were treated with various concentrations of lithium chloride to evaluate its inflammatory and anticancer properties. The in vitro cytotoxic effects of lithium chloride were assessed using the MTT [3-(4, 5-dimethythiazol-2-yl)-2, 5-diphenyltetrazolium bromide] assay, Muse® cell death, and cell cycle analysis. The nitric oxide and oxidative stress flow cytometry Muse® assays were used to monitor inflammation profiles of lithium-treated lung adenocarcinoma cells. The MTT viability assay showed the safe use of LiCl on the noncancerous RAW 264.7 macrophage cells below a concentration of 40 mM. Lithium reduced cell viability, induced late apoptotic cell death, and disrupted normal cell cycle progression in a dose-dependent manner, leading to cell cycle arrest in the S and G2/M phases of A549 cells. The induction of cell death by lithium in A549 cells is accompanied by increased ROS and nitric oxide production. This study shows that lithium chloride possesses some immunomodulatory cytotoxic effects on A549 lung cancer cells and can be further investigated for use in lung cancer treatment.

19 March 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
PRPearl Ramushu
Pearl Ramushu
DMDikgale Francina Mangoakoana
Dikgale Francina Mangoakoana
RMRaymond Makola
Raymond Makola
TMTHABE MATSEBATLELA
THABE MATSEBATLELA
Lithium has been identified more than 6 decades ago as a preferred treatment option for manic depression. As a result of its affordability, stability, minimal side effects, and immunomodulatory effects, recent lithium studies have focused on its anti-cancer potential and possible mechanism of action. Lung cancer ranks the highest as the main cause of death in males and has high mortality rates with low survival rates. In this study, lung adenocarcinoma (A549) cells were treated with various concentrations of lithium chloride to evaluate its anti-inflammatory and anti-cancer effects. The in vitro cytotoxic effects of lithium chloride were assessed using the MTT [3-(4, 5-dimethythiazol-2-yl)-2, 5-diphenyltetrazolium bromide] assay, Muse® cell death and cell cycle analysis. The Nitric oxide and oxidative stress flow cytometry Muse® assays were used to monitor inflammation profiles of lithium-treated lung adenocarcinoma cells. The MTT viability assay showed safe use of LiCl on the noncancerous Raw 264.7 macrophage cells below the concentration of 40 mM. Lithium reduced cell viability, induces late apoptotic cell death, and disrupts normal cell cycle progression in a dose-dependent manner, leading to cell cycle arrest in the S and G2/M phases of A549 cells. The induction of cell death by lithium in A549 cells accompanied increased ROS and nitric oxide production. This study shows that lithium chloride possess some immunomodulatory cytotoxic effects on A549 lung cancer cells and can be further investigated for use in lung cancer treatment.